These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3886191)

  • 21. The long-term efficacy of ibopamine in treating patients with severe heart failure: a multicenter investigation.
    Condorelli M; Bonaduce A; Montemurro A; Mattioli G; Cappello C; Caponnetto S; Terrachini V; Canale C; Varricchio M; Cacciapuoti F
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S83-92. PubMed ID: 2483445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy.
    Leier CV; Dalpiaz K; Huss P; Hermiller JB; Magorien RD; Bashore TM; Unverferth DV
    Am J Cardiol; 1983 Aug; 52(3):304-8. PubMed ID: 6683463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group.
    Goldberg AD; Nicklas J; Goldstein S
    Am J Cardiol; 1991 Sep; 68(6):631-6. PubMed ID: 1715125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Amrinone in acute and long-term therapy].
    Klepzig M; Kleinhans E; Büll U; Strauer BE
    Z Kardiol; 1985 Feb; 74(2):85-90. PubMed ID: 3922139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure.
    Zipperle G; Butzer F; Dieterich HA; Heinrich F
    Am J Cardiol; 1987 Aug; 60(5):72C-74C. PubMed ID: 2956873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease.
    Maskin CS; Forman R; Klein NA; Sonnenblick EH; LeJemtel TH
    Am J Med; 1982 Jan; 72(1):113-8. PubMed ID: 7058816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effects of intravenous amrinone in patients with congestive heart failure.
    Goldstein RA
    Circulation; 1986 Mar; 73(3 Pt 2):III191-5. PubMed ID: 3510775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind crossover comparison of enoximone and placebo in patients with congestive heart failure.
    Choraria SK; Taylor D; Pilcher J
    Circulation; 1987 Dec; 76(6):1307-11. PubMed ID: 2960473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous amrinone for congestive heart failure.
    Med Lett Drugs Ther; 1984 Nov; 26(675):104-5. PubMed ID: 6390109
    [No Abstract]   [Full Text] [Related]  

  • 30. Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure.
    LeJemtel TH; Keung E; Ribner HS; Davis R; Wexler J; Blaufox JD; Sonnenblick EH
    Am J Cardiol; 1980 Jan; 45(1):123-9. PubMed ID: 7350759
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of amrinone on right ventricular function: predominance of afterload reduction.
    Konstam MA; Cohen SR; Salem DN; Das D; Aronovitz MJ; Brockway BA
    Circulation; 1986 Aug; 74(2):359-66. PubMed ID: 3731426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical safety of intravenous amrinone--a review.
    Treadway G
    Am J Cardiol; 1985 Jul; 56(3):39B-40B. PubMed ID: 3895878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous use of amrinone for the treatment of the failing heart.
    Mancini D; LeJemtel T; Sonnenblick E
    Am J Cardiol; 1985 Jul; 56(3):8B-15B. PubMed ID: 2411122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure.
    Siegel LA; Keung E; Siskind SJ; Forman R; Feinberg H; Strom J; Efstathakis D; Sonnenblick EH; LeJemtel TH
    Circulation; 1981 Apr; 63(4):838-44. PubMed ID: 7471340
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term treatment with oral enoximone for chronic congestive heart failure: the European experience.
    Treese N; Erbel R; Pilcher J; Choraria S; Rhein S; Dieterich HA; Meyer J
    Am J Cardiol; 1987 Aug; 60(5):85C-90C. PubMed ID: 2956876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate.
    Bayliss J; Norell M; Canepa-Anson R; Reuben SR; Poole-Wilson PA; Sutton GC
    Br Heart J; 1983 Mar; 49(3):214-21. PubMed ID: 6830658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of intravenous amrinone: the first of a new class of positive inotropic agents with vasodilator properties.
    Bottorff MB; Rutledge DR; Pieper JA
    Pharmacotherapy; 1985; 5(5):227-37. PubMed ID: 3906583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of isosorbide-5-mononitrate on exercise performance and clinical status in patients with congestive heart failure. Results of the Nitrates in Congestive Heart Failure (NICE) Study.
    Lewis BS; Rabinowitz B; Schlesinger Z; Caspi A; Markiewicz W; Rosenfeld T; Sclarovsky S; Ermer W
    Cardiology; 1999; 91(1):1-7. PubMed ID: 10393392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study.
    Markham RV; Corbett JR; Gilmore A; Pettinger WA; Firth BG
    Am J Cardiol; 1983 May; 51(8):1346-52. PubMed ID: 6342353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group.
    Narahara KA
    Am Heart J; 1991 May; 121(5):1471-9. PubMed ID: 1826806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.